Public health agency the US Food and Drug Administration (FDA) said on Tuesday that it has currently authorised 203 tests under EUAs, including 166 molecular tests, 35 antibody tests and two antigen tests to date in the ongoing response to the COVID-19 pandemic.
The agency added that it has updated its COVID-19 Drug Shortages Response webpage to provide information regarding in-use time for certain drugs during the COVID-19 public health emergency.
To protect consumers, the agency has also issued a warning letter jointly with the Federal Trade Commission to MMSTabs.com for selling unapproved and unauthorized products to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.
In addition, the agency has issued Emergency Use Authorizations (EUAs) for COVID devices and tests to Abiomed Inc, Cleveland Clinic Robert J. Tomsich Pathology and Laboratory Medicine Institute, Poplar Healthcare, Wren Laboratories LLC as well as Ethos Laboratories.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval